IL2 and immunoglobulin G4-related sclerosing disease: Furthermore, since the account of circulating CD28- CTLs increased in patients with IgG4-RD, tofacitinib inhibits IL-2 signaling, which induces CTL proteome and effector molecules, indicating that CTLs could be a potential target for the treatment of IgG4-RD with this drug.